FDA Approves Leucovorin for Autism Treatment

FDA Approval of Leucovorin for Autism

• FDA is initiating a label change for prescription Leucovorin, a folate supplement, to make it available for children with autism.
• This approval is based on research suggesting autism may be linked to an autoimmune reaction affecting folate transport to brain cells.
• A study indicated that two-thirds of children with autism and chronic folate deficiency experienced improvement in symptoms after treatment.

Administration's Response to Autism Crisis

• The administration is taking a bold, accelerated approach to address the rise in autism diagnoses, moving beyond traditional agency silos.
• This is the first FDA-recognized treatment pathway for autism, driven by the President's and Secretary Kennedy's commitment.
• The five-fold increase in autism prevalence over 25 years necessitates a rapid response, moving faster than the typical five-year research timeline.

Access and Data Collection for Leucovorin

• Over half of American children are covered by Medicaid and CHIP, ensuring that state Medicaid programs will cover prescription Leucovorin.
• Private insurance companies are expected to follow suit, with physicians required to prescribe the medication.
• CMS is issuing guidance to collect real-world clinical data to support ongoing research efforts by NIH and FDA, while maintaining patient privacy.
• This approach aims to provide answers quickly and ensure the right children receive the appropriate treatment.